Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Dow
Queensland Health
Fish and Richardson
US Army
Chinese Patent Office
Cantor Fitzgerald
Cerilliant
Merck
Mallinckrodt

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,865,688

« Back to Dashboard

Which drugs does patent 8,865,688 protect, and when does it expire?

Patent 8,865,688 protects APRISO and is included in one NDA.

This patent has fifteen patent family members in twelve countries.
Summary for Patent: 8,865,688
Title:Compositions and methods for treatment of bowel diseases with granulated mesalamine
Abstract: Disclosed are methods for treating gastrointestinal disorders, e.g., Crohn's disease, ulcerative colitis, and diverticular disease, with a granulated mesalamine formulation. Some formulations use granulated mesalamine in capsule form. Also included are methods to extend remission of ulcerative colitis by administration of a once-daily dosage of granulated mesalamine.
Inventor(s): Forbes; William (Raleigh, NC)
Assignee: Dr. Falk Pharma GmbH (DE)
Application Number:12/573,081
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,865,688

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant Pharms Intl APRISO mesalamine CAPSULE, EXTENDED RELEASE;ORAL 022301-001 Oct 31, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,865,688

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2739465 ➤ Try a Free Trial
China 102238868 ➤ Try a Free Trial
Eurasian Patent Organization 201100565 ➤ Try a Free Trial
Eurasian Patent Organization 022886 ➤ Try a Free Trial
European Patent Office 2334178 ➤ Try a Free Trial
Israel 212057 ➤ Try a Free Trial
Japan 2012504658 ➤ Try a Free Trial
Japan 5740306 ➤ Try a Free Trial
Mexico 2011003595 ➤ Try a Free Trial
New Zealand 592049 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Baxter
Harvard Business School
McKesson
US Army
Chinese Patent Office
Federal Trade Commission
Healthtrust
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot